When to monitor and how For patients on FDA-approved GLP-1 drugs, reasonable monitoring approach: Document baseline BP before starting Home BP monitor for patients with baseline hypertension or on antihypertensives
Typically, candidates for tirzepatide for weight loss include: Adults with a body mass index (BMI) of 30 kg/m or greater (classified as obesity) Adults with a BMI of 27 kg/m or greater who also have at least one weight-related health condition, such as type 2 diabetes, high blood pressure, or high cholesterol Tirzepatide is not intended for individuals with a personal or family history of medullary thyroid carcinoma, those with multiple endocrine neoplasia syndrome type 2, or anyone with a known hypersensitivity to the medication
McIntosh CH, Widenmaier S, Kim S-J
Hes shared that focusing on mindset helped unlock meaningful non-scale victories , including better sleep, improved intimacy, more confidence, and clearer thinking